Latent Tuberculosis Infection in Bone Marrow Transplant Recipients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01021124|
Recruitment Status : Completed
First Posted : November 26, 2009
Last Update Posted : July 18, 2013
|Condition or disease|
All adult bone marrow transplant recipients admitted to Asan Medical Center will be enrolled.
Quantiferon-Gold In-Tube assay will be performed.
Isoniazid prophylaxis will be given only to patients with clinical risk factors (i.e. recent contact with active pulmonary TB patient or inadequate treatment history with abnormal CXR). However, isoniazid prophylaxis will be not given based on positive TST or positive Quantiferon-Gold In-Tube assay.
|Study Type :||Observational|
|Actual Enrollment :||409 participants|
|Official Title:||A Prospective Observational Study of Usefulness of a T Cell-based Assay for Latent Tuberculosis Infection in Hematopoietic Stem Cell Transplant Recipients|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||June 2013|
|Actual Study Completion Date :||June 2013|
|QFT (+) vs QFT (-)|
- development of tuberculosis [ Time Frame: after transplantation ]
- all cause mortality [ Time Frame: after transplantation ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01021124
|Korea, Republic of|
|Asan Medical Center|
|Seoul, Korea, Republic of, 138-736|
|Principal Investigator:||Sung-Han Kim, MD||Asan Medical Center|